Scientists test drug combo in fight against rare, spreading eye cancer
NCT ID NCT01979523
Summary
This study is testing whether adding a second drug (GSK2141795) to an existing cancer medication (trametinib) works better for controlling advanced uveal melanoma, a rare cancer that starts in the eye and has spread. It enrolled 42 patients who had not received prior drug treatment for their advanced disease. The main goal is to see which approach keeps the cancer from growing longer and is better tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV UVEAL MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Institut Curie Paris
Paris, 75005, France
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
The University of Liverpool
Liverpool, L69 3GA, United Kingdom
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.